TrialAnnals of clinical and translational neurology2026

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants.

Ralf Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.